Improving saliva and tear production in Sjögren's syndrome
Targeting P2 Receptors to Restore Salivary and Lacrimal Gland Function in Sjogren's Syndrome
This study is looking at how blocking certain receptors in the glands that produce saliva and tears might help people with Sjögren's syndrome, a condition that causes dry mouth and dry eyes, by improving their gland function and making them feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11041086 on NIH RePORTER |
What this research studies
This research investigates how targeting specific receptors in the salivary and lacrimal glands can help restore their function in patients with Sjögren's syndrome, an autoimmune condition that leads to dry mouth and dry eyes. The study focuses on the P2X7 and P2Y2 receptors, which are involved in the inflammatory response and fluid secretion. By using antagonists to block these receptors, the researchers aim to enhance saliva and tear production, potentially improving the quality of life for affected individuals. The approach is based on findings from mouse models that show promising results in increasing gland function and reducing inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Sjögren's syndrome who experience symptoms of dry mouth and dry eyes.
Not a fit: Patients who do not have Sjögren's syndrome or those with other unrelated conditions affecting saliva and tear production may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve saliva and tear production for patients suffering from Sjögren's syndrome.
How similar studies have performed: Previous research has shown success in targeting similar receptors for improving gland function, indicating a promising avenue for treatment development.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Weisman, Gary Andrew — University of Missouri-Columbia
- Study coordinator: Weisman, Gary Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.